Effect of IL-17 in the development of colon cancer in mice

Yang, Lijuan; Líu, Hao; Zhang, Lili; Hu, Jie; Chen, Hạixia; Wang, Lei; Yin, Xiaolin; Li, Quanhai; Qi, Yixin

doi:10.3892/ol.2016.5329

Cited by 13 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, Kryczek et al reported that subcutaneous injection of the MC38 murine colon cancer cell line into IL-17-deficient mice resulted in faster growth and increased lung metastasis foci compared to that of wildtype control mice (85). Previous studies have demonstrated that the antitumor effect of IL-17 in various cancer types is related to enhanced recruitment and activity of lymphocytes, natural killer (NK) cells, and DCs into the tumor site and production of the antitumor cytokine IFN-γ (86–89). Lin et al showed that CRC patients with higher IL-17 levels tend to have a better prognosis than those with lower IL-17 levels (90).…”

Section: The Role Of Th9/il-9 Th17/il-17 and Th22/il-22 In The Devementioning

confidence: 99%

TH9, TH17, and TH22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer

Cui

2019

Front. Oncol.

View full text Add to dashboard Cite

In recent years, several newly identified T helper (TH) cell subsets, such as TH9, TH17, and TH22 cells, and their respective cytokine products, IL-9, IL-17, and IL-22, have been reported to play critical roles in the development of chronic inflammation in the colorectum. Since chronic inflammation is a potent driving force for the development of human colorectal cancer (CRC), the contributions of TH9/IL-9, TH17/IL-17, and TH22/IL-22 in the pathogenesis of CRC have recently become an increasingly popular area of scientific investigation. Extensive laboratory and clinical evidence suggests a positive relationship between these new TH subsets and the growth and formation of CRC, whereas, administration of IL-9, IL-17, and IL-22 signaling inhibitors can significantly alter the formation of colorectal chronic inflammation or CRC lesions in animal models, suggesting that blocking these cytokine signals might represent promising immunotherapeutic strategies. This review summarizes recent findings and currently available data for understanding the vital role and therapeutic significance of TH9/IL-9, TH17/IL-17, and TH22/IL-22 in the development of colorectal tumorigenesis.

show abstract

Section: The Role Of Th9/il-9 Th17/il-17 and Th22/il-22 In The Devementioning

confidence: 99%

TH9, TH17, and TH22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer

Cui

2019

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In this study IL-17concentration was significantly elevated after the drug modality that promotes to control the adenocarcinoma of colon. It was revealed that PUMA controlled tumour growth by inhibiting cell cycle progression and by stimulating apoptosis [17]. In this study, the concentration of PUMA was increased after treatment.…”

Section: Resultsmentioning

confidence: 54%

Therapeutic effect of the Indigenous drug modality in the management of Adenocarcinoma of colon – A case report based on cytokines expressions

Lhs¹,

Eps

Apg

2021

ijacare

View full text Add to dashboard Cite

A clinical study was conducted from May to July 2017 in the outpatient department of Bandaranaike Memorial Ayurvedic Research Institute (BMARI), Navinna, Sri Lanka to test the antitumor activity of the indigenous drug modality which is used to manage the colon cancer. A forty year old colon cancer patient volunteered to the study. Ethical approval has been taken from the Institute of Indigenous Medicine, University of Colombo Sri Lanka. Detailed history, clinical examinations and relevant investigations were conducted at BMARI and the Department of Zoology, Faculty of Science, University of Ruhuna. Three herbal formulations namely SG powder- 5g/day, KY powder -10g/day and A1 powder -10g/day were given for the patient throughout 90 days of study. Serum Interleukin-2 (IL-2), Interleukin-5 (IL-5), Interleukin 17 (IL-17), Interferon (IFN)-ɣ and p53 Upregulated Modulator of Apoptosis (PUMA) were quantified using Enzyme-Linked Immunosorbent Assay (ELISA) before and after the treatments (after 45 and 90 days) as these cytokines play a significant role in tumor growth control. Tumor marker expression and stool samples were tested before and after treatments (after 45 and 90 days). Symptoms of colon cancer were significantly decreased during the treatment along with changes in tumor markers. According to the results of the ELISA, IL-2, IFN-ɣ and IL-17 concentrations were increased significantly after the treatment and expression level increased in all three cytokines over time indicating the possible control of colon cancer growth by the drug modality. Further investigations are required to evaluate the mechanism of effectiveness of this indigenous drug modality in controlling carcinoma of colon.

show abstract

“…In this study, the data showed that IL-17 expression had a negative correlation with the expression of FAS and FASL. A previous study highlighted IL-17 to be a potential prognostic marker for patients with respiratory, digestive, and other system cancers [ 13 ]. In addition, IL-17 may be significantly correlated with the differentiation and angiogenesis in the development of LC as the expression of CXCL9, CXCL10, and IL-17 mRNAs in the skin of FAS- and FASL-deficient mice was decreased [ 27 , 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

IL-17 Affects the Progression, Metastasis, and Recurrence of Laryngeal Cancer via the Inhibition of Apoptosis through Activation of the PI3K/AKT/FAS/FASL Pathways

Song

Yang

Zhang

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Background. Cytokines play important roles in the development and prognosis of laryngeal cancer (LC). Interleukin-17 (IL-17) from a distinct subset of CD4+ T cells may significantly induce cancer-elicited inflammation to prevent tumor immune surveillance. Methods. The expression levels of IL-17 were examined among 60 patients with LC. Immunofluorescence colocalization experiments were performed to verify the localization of IL-17 and FAS/FASL in Hep-2 and Tu212 cells. The role of IL-17 was determined using siRNA techniques in the LC cell line. Results. In the LC patients, cytokines were dysregulated in LC tissues compared with normal tissues. It was found that IL-17 was overexpressed in a cohort of 60 LC tumors paired with nontumor tissues. Moreover, high IL-17 expression was significantly associated with the advanced T category, the late clinical stage, differentiation, lymph node metastasis, and recurrence. In addition, the time course expression of FAS and FASL was observed after stimulation and treatment with the IL-17 stimulator. Finally, in vitro experiments demonstrated that IL-17 functioned as an oncogene by inhibiting the apoptosis of LC cells via the PI3K/AKT/FAS/FASL pathways. Conclusions. In summary, these findings demonstrated for the first time the role of IL-17 as a tumor promoter and a prometastatic factor in LC and indicated that IL-17 may have an oncogenic role and serve as a potential prognostic biomarker and therapeutic target in LC.

show abstract

Effect of IL-17 in the development of colon cancer in mice

Cited by 13 publications

References 21 publications

TH9, TH17, and TH22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer

TH9, TH17, and TH22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer

Therapeutic effect of the Indigenous drug modality in the management of Adenocarcinoma of colon – A case report based on cytokines expressions

IL-17 Affects the Progression, Metastasis, and Recurrence of Laryngeal Cancer via the Inhibition of Apoptosis through Activation of the PI3K/AKT/FAS/FASL Pathways

Contact Info

Product

Resources

About